



FDA ADVISORY  
No. **2018-011**

23 JAN 2018

**TO: THE GENERAL PUBLIC**

**SUBJECT: Lifting the Advisory of QUANTUMIN PLUS under FDA Advisory No. 2017-268, Subject "Public Health Warning Against the Unapproved and Misleading Advertisement and Promotion of Quantumin Plus"**

This is to inform the public that the Advisory of the product "QUANTUMIN PLUS" under FDA Advisory No. 2017-268 dated 19 September 2017 is hereby lifted pursuant to company's compliance with rules and regulations of this Office.



Figure 1. QUANTUMIN PLUS

The company has conducted withdrawal and destruction of non-compliant promotional materials. Further, it has amended its "Member's Term and Conditions" to emphasize that Quantumin Plus is a food supplement, with no therapeutic claims and should not be recommended for use in the prevention, treatment or cure of any disease. Any member committing violation of stated code of ethics, terms, policy and conditions shall be penalized by the company after their proper evaluation.



Finally, the issuance of this advisory shall not in any manner preclude this Office from issuing subsequent orders it may deem necessary and appropriate, should there be findings of any violation of existing laws, rules, and regulations.

For more information and inquiries, please e-mail us at [info@fda.gov.ph](mailto:info@fda.gov.ph) or call us at FDA Action Center hotline (02) 821-1162.

Dissemination of the information to all concerned is requested.

  
**NELA CHARADE G. PUNO, RPh**  
Director General ✓

DTN 20171214111146